Developer docs
API playgroundTry for free, no card

Search company profiles

Bactolife

Full company profile

uuid0000t1w

Namestring
Bactolife
Legal namestring
Bactolife A/S
Websiteurl
bactolife.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Bactolife A/S is a Danish biotechnology company founded in 2017 and headquartered in Copenhagen, developing proprietary Binding Proteins™ — milk-inspired proteins derived from natural camelid immunoglobulins and manufactured via scalable precision fermentation. The proteins selectively bind and neutralize undesired microbes and their metabolites in the gastrointestinal tract without disrupting the beneficial microbiome, offering a mechanism distinct from probiotics, prebiotics, or antibiotics. The technology is validated in animal models (6,000+ piglets tested) and is being translated into multiple target segments including mothers and children (with primary focus on infant formula applications), elderly gut health, immunodeficient individuals, travelers/deployed personnel, and animal feed (notably a zinc-oxide alternative for piglets).

The company operates as a B2B ingredient supplier, selling Binding Protein ingredients to food, beverage, dietary supplement, and animal feed manufacturers. Its human health ingredient brand, Helm™, is scheduled for first US launch in 2026, with EU and Asia expansion to follow; APAC entry is anchored by a strategic partnership with Korean probiotic leader AceBiome for combination products. Revenue streams span one-time/licensing sales of food and feed ingredients, with future licensing/royalty potential under the Helm brand. The company is venture-backed (over EUR 67 million raised across seed, Series A, Series B, and Gates Foundation grants), with no commercial revenue disclosed as of the input data, positioning it as a pre-commercial bioindustrial scale-up.

Short descriptiontext

Bactolife is a Danish biotech that develops Binding Proteins™, milk-inspired ingredients produced via precision fermentation that selectively bind harmful gut metabolites, selling them as B2B ingredients to food, supplement, and feed manufacturers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gut health ingredients, binding proteins, functional food ingredients, animal feed additives, precision fermentation
Industry1 code
PRIMARYAFAHAHAJ
Specialized Dairy Nutrition Base Powder & Premix Manufacturing (Vitamin/Mineral/Functional Premixes)
Agriculture & Food Production/Dairy Processing/Infant Formula & Specialized Dairy Nutrition Manufacturing
NAICS code1 code
  • Animal Food Manufacturing3111
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gut Health Biotech Ingredients
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Food Ingredient Sales
TypeOne Time License
Description

Bactolife develops and sells Binding Protein ingredients to food, beverage, and dietary supplement manufacturers. These ingredients are incorporated into functional foods, infant formula, dietary supplements, and other consumer health products.

bactolife.com
2Feed Ingredient Sales
TypeOne Time License
Description

Binding Proteins are sold as specialty feed ingredients for animal health applications, supporting gut balance in production animals such as piglets.

bactolife.com
3Ingredient Licensing (Helm Brand)
TypeLicensing Royalties
Description

Products launched under the Helm ingredient brand for human health applications, targeting dietary supplements, functional food and beverages. First human health product launch planned for US in 2026.

bactolife.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Helm
Description

Ingredient brand for Binding Proteins, used for human health applications. Launch planned for US market in 2026.

bactolife.com
Core offering1 text field

Bactolife develops and manufactures proprietary Binding Proteins — milk-inspired proteins derived from natural camelid immunoglobulins that selectively bind and neutralize harmful microbes and their metabolites in the gastrointestinal tract without disrupting beneficial microbiome components. These proteins are produced via scalable precision fermentation and sold as functional ingredients to food, beverage, dietary supplement, and animal feed manufacturers under the Helm™ brand for human health applications and as dedicated animal health feed additives.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Demonstrated efficacy in 6,000+ piglets for animal health applications
+1 more record
Product overview1 text field

Bactolife is a Danish biotech company offering Binding Proteins™ as its core technology platform—a portfolio of milk-inspired, precision-engineered proteins produced via scalable microbial fermentation. The main product line is branded as Helm™ Binding Proteins for human health applications, including dietary supplements, functional foods, and beverages. The company also provides animal health feed additives. Products are segmented by consumer groups: mothers & children, elderly, immunodeficient individuals, travelers & deployed personnel, and production animals. The technology selectively binds and neutralizes undesired metabolites while preserving beneficial microbiome components.

Product and service3 records
1Binding Proteins™
CategoryFunctional Biotech Ingredients
Description

Proprietary milk-inspired proteins derived from natural camelid immunoglobulins that selectively bind and neutralize undesired microbes and their metabolites in the gastrointestinal tract without disrupting beneficial microbiome components. Produced through precision fermentation using a scalable microbial manufacturing platform and sold as functional ingredients to food, beverage, dietary supplement, and animal feed manufacturers for incorporation into infant formula, functional foods, dietary supplements, beverages, and specialty feed formulations.

2Helm™ Binding Proteins
CategoryHuman Health Functional Ingredients
Description

The branded ingredient line for Bactolife's human health applications, providing animal-free and vegan-friendly Binding Protein ingredients for dietary supplements, functional foods, and beverages. First commercial launch planned for the US market in 2026 with subsequent expansion into EU and Asia.

3Animal Health Feed Additives
CategoryAnimal Feed Additives
Description

Binding Protein feed additives for production animals, particularly piglets, providing a sustainable alternative to supplemental zinc oxide for managing post-weaning dysbiosis and supporting gut balance, animal welfare, and economic viability of farming operations. Validated efficacy demonstrated in more than 6,000 piglets.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-26
Description

Korean microbiome and probiotic company, market leader in probiotics within Korea. Strategic partnership to launch the first probiotic-Binding Protein combination product in Korea, combining Helm Binding Proteins with AceBiome's probiotic strains. APAC expansion partner with focus on Southeast Asia.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Academic research partner. Professor Lone Gram from DTU serves on Bactolife's Scientific Advisory Board. Collaborates on gut microbiome research and Binding Protein development.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Academic research partner. Professor Fredrik Bäckhed from University of Gothenburg serves on Bactolife's Scientific Advisory Board, bringing expertise in molecular and clinical medicine.

4SEGES Danish Pig Research Center
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Industry research partner collaborating on alternative solutions to zinc oxide in pig farming. Part of project supported by Danish Ministry of Environment and Food (GUDP program).

bactolife.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Academic partner in collaborative project to develop alternatives to zinc oxide for pig farming. Working with Bactolife, DTU, and SEGES on sustainable animal health solutions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Novonesis was formed through the merger of Novozymes and Chr. Hansen in 2024 and is the global leader in precision fermentation for food, beverage, and animal nutrition ingredients — including probiotics, cultures, enzymes, and bioactive proteins. It is the most direct incumbent comparable to Bactolife, with overlapping precision-fermentation technology, food/feed customer base, and gut-health category positioning. Bactolife's CEO and COO both come from Novozymes.

2BioGaia
TypeDirect peer
Description

Swedish probiotics specialist developing Lactobacillus and Bifidobacterium strains for gut health, sold as dietary supplements and as functional food/infant formula ingredients globally. Direct peer to Bactolife in the gut-health ingredient category, though BioGaia's mechanism (probiotics) differs from Binding Proteins; both target infant formula, supplements, and clinical nutrition.

TypeBroad incumbent
Description

Global food and animal nutrition company with a large postbiotics and gut-health ingredients business (formerly through the Diamond V and postbiotic acquisitions). Overlaps with Bactolife in B2B functional ingredient sales to food, beverage, dietary supplement, and animal feed manufacturers. Bactolife's SVP US Liz Spence was previously Commercial Director and GM of Cargill's postbiotic business.

TypeBroad incumbent
Description

Global nutrition and agricultural processor with a large-scale human and animal nutrition ingredients business, including flavors, probiotics, and functional ingredients produced via fermentation. Comparable to Bactolife in B2B food and feed ingredient supply, with significantly larger scale and customer reach.

TypeBroad incumbent
Description

Irish-headquartered global taste and nutrition company selling ingredients (probiotics, postbiotics, enzymes, bioactive proteins) to food, beverage, and supplement manufacturers. Comparable to Bactolife in B2B functional ingredient sales, with adjacent gut-health technology (including GanedenBC30 probiotics) and broader portfolio diversification.

TypeBroad incumbent
Description

Global ingredients company with a Health & Biosciences division producing cultures, probiotics, enzymes, and food ingredients via microbial fermentation (via the Danisco acquisition). Comparable to Bactolife in precision-fermentation-derived functional ingredients, with greater scale and broader category coverage.

TypeEmerging player
Description

US-based precision fermentation company producing animal-free whey and casein proteins for food and nutrition applications using a similar fermentation platform to Bactolife's. Comparable as a fellow precision-fermentation functional protein company targeting B2B food and nutrition customers, though Perfect Day focuses on dairy-analogue proteins rather than gut-health binding proteins.

TypeEmerging player
Description

US-based precision fermentation company (formerly Clara Foods) producing animal-free egg proteins and other functional proteins via microbial fermentation. Comparable to Bactolife in precision-fermentation-derived functional proteins targeting food and supplement applications, with a similar B2B ingredient business model.

9Lallemand
TypeRegional player
Description

Canadian-headquartered global producer of yeast, bacteria, and fermentation-derived ingredients for food, beverage, animal nutrition, and human health applications. Comparable to Bactolife in fermentation-derived functional ingredients and in animal feed (probiotics) for swine — a directly overlapping customer base in piglet gut health.

TypeEmerging player
Description

Dutch B2B ingredients startup producing precision-fermentation dairy proteins (whey, casein) for food, beverage, and nutrition applications. Comparable to Bactolife as a fellow emerging precision-fermentation protein company targeting the B2B functional food ingredient market, with similar technology platform and growth stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles23 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bactolife

Gut Health Biotech Ingredientsbactolife.com

Bactolife is a Danish biotech that develops Binding Proteins™, milk-inspired ingredients produced via precision fermentation that selectively bind harmful gut metabolites, selling them as B2B ingredients to food, supplement, and feed manufacturers.

What Bactolife does

Bactolife A/S is a Danish biotechnology company founded in 2017 and headquartered in Copenhagen, developing proprietary Binding Proteins™ — milk-inspired proteins derived from natural camelid immunoglobulins and manufactured via scalable precision fermentation. The proteins selectively bind and neutralize undesired microbes and their metabolites in the gastrointestinal tract without disrupting the beneficial microbiome, offering a mechanism distinct from probiotics, prebiotics, or antibiotics. The technology is validated in animal models (6,000+ piglets tested) and is being translated into multiple target segments including mothers and children (with primary focus on infant formula applications), elderly gut health, immunodeficient individuals, travelers/deployed personnel, and animal feed (notably a zinc-oxide alternative for piglets).

The company operates as a B2B ingredient supplier, selling Binding Protein ingredients to food, beverage, dietary supplement, and animal feed manufacturers. Its human health ingredient brand, Helm™, is scheduled for first US launch in 2026, with EU and Asia expansion to follow; APAC entry is anchored by a strategic partnership with Korean probiotic leader AceBiome for combination products. Revenue streams span one-time/licensing sales of food and feed ingredients, with future licensing/royalty potential under the Helm brand. The company is venture-backed (over EUR 67 million raised across seed, Series A, Series B, and Gates Foundation grants), with no commercial revenue disclosed as of the input data, positioning it as a pre-commercial bioindustrial scale-up.

Bactolife firmographics

Firmographics
Name
Bactolife
Legal name
Bactolife A/S
Website
https://bactolife.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Bactolife is a Danish biotech that develops Binding Proteins™, milk-inspired ingredients produced via precision fermentation that selectively bind harmful gut metabolites, selling them as B2B ingredients to food, supplement, and feed manufacturers.
Ownership category
akta.pro rank

Bactolife industry classification

Industry
Product category
Gut Health Biotech Ingredients
NAICS
Animal Food Manufacturing (3111)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYAFAHAHAJ
Specialized Dairy Nutrition Base Powder & Premix Manufacturing (Vitamin/Mineral/Functional Premixes)
Agriculture & Food Production/Dairy Processing/Infant Formula & Specialized Dairy Nutrition Manufacturing

Keywords

  • Gut health ingredients
  • Binding proteins
  • Functional food ingredients
  • Animal feed additives
  • Precision fermentation

Where Bactolife is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices2 records

Markets served

Bactolife business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Food Ingredient Sales: Bactolife develops and sells Binding Protein ingredients to food, beverage, and dietary supplement manufacturers. These ingredients are incorporated into functional foods, infant formula, dietary supplements, and other consumer health products.
  2. Feed Ingredient Sales: Binding Proteins are sold as specialty feed ingredients for animal health applications, supporting gut balance in production animals such as piglets.
  3. Ingredient Licensing (Helm Brand): Products launched under the Helm ingredient brand for human health applications, targeting dietary supplements, functional food and beverages. First human health product launch planned for US in 2026.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Bactolife product offering

Product offering

Core offering

Bactolife develops and manufactures proprietary Binding Proteins — milk-inspired proteins derived from natural camelid immunoglobulins that selectively bind and neutralize harmful microbes and their metabolites in the gastrointestinal tract without disrupting beneficial microbiome components. These proteins are produced via scalable precision fermentation and sold as functional ingredients to food, beverage, dietary supplement, and animal feed manufacturers under the Helm™ brand for human health applications and as dedicated animal health feed additives.

Product overview

Bactolife is a Danish biotech company offering Binding Proteins™ as its core technology platform—a portfolio of milk-inspired, precision-engineered proteins produced via scalable microbial fermentation. The main product line is branded as Helm™ Binding Proteins for human health applications, including dietary supplements, functional foods, and beverages. The company also provides animal health feed additives. Products are segmented by consumer groups: mothers & children, elderly, immunodeficient individuals, travelers & deployed personnel, and production animals. The technology selectively binds and neutralizes undesired metabolites while preserving beneficial microbiome components.

Differentiator

Problem solved

Functional benefit

Brands

  • Helm: Ingredient brand for Binding Proteins, used for human health applications. Launch planned for US market in 2026.

Products and services

  • Binding Proteins™ Proprietary milk-inspired proteins derived from natural camelid immunoglobulins that selectively bind and neutralize undesired microbes and their metabolites in the gastrointestinal tract without disrupting beneficial microbiome components. Produced through precision fermentation using a scalable microbial manufacturing platform and sold as functional ingredients to food, beverage, dietary supplement, and animal feed manufacturers for incorporation into infant formula, functional foods, dietary supplements, beverages, and specialty feed formulations.
  • Helm™ Binding Proteins The branded ingredient line for Bactolife's human health applications, providing animal-free and vegan-friendly Binding Protein ingredients for dietary supplements, functional foods, and beverages. First commercial launch planned for the US market in 2026 with subsequent expansion into EU and Asia.
  • Animal Health Feed Additives Binding Protein feed additives for production animals, particularly piglets, providing a sustainable alternative to supplemental zinc oxide for managing post-weaning dysbiosis and supporting gut balance, animal welfare, and economic viability of farming operations. Validated efficacy demonstrated in more than 6,000 piglets.

Quantifiable outcome

  • Demonstrated efficacy in 6,000+ piglets for animal health applications
  • +1 more outcomes

Companies that use Bactolife

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Bactolife technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Bactolife partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and major.

  • AceBiomecoreStrategic or Co-development Partner · 26 January 2026Korean microbiome and probiotic company, market leader in probiotics within Korea. Strategic partnership to launch the first probiotic-Binding Protein combination product in Korea, combining Helm Binding Proteins with AceBiome's probiotic strains. APAC expansion partner with focus on Southeast Asia.
  • Technical University of Denmark (DTU)majorStrategic or Co-development PartnerAcademic research partner. Professor Lone Gram from DTU serves on Bactolife's Scientific Advisory Board. Collaborates on gut microbiome research and Binding Protein development.
  • University of GothenburgmajorStrategic or Co-development PartnerAcademic research partner. Professor Fredrik Bäckhed from University of Gothenburg serves on Bactolife's Scientific Advisory Board, bringing expertise in molecular and clinical medicine.
  • SEGES Danish Pig Research CentermajorStrategic or Co-development PartnerIndustry research partner collaborating on alternative solutions to zinc oxide in pig farming. Part of project supported by Danish Ministry of Environment and Food (GUDP program).
  • Aarhus UniversitymajorStrategic or Co-development PartnerAcademic partner in collaborative project to develop alternatives to zinc oxide for pig farming. Working with Bactolife, DTU, and SEGES on sustainable animal health solutions.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Bactolife competitors and assessment

Company assessment

Broad incumbents

  • Novonesis: Novonesis was formed through the merger of Novozymes and Chr. Hansen in 2024 and is the global leader in precision fermentation for food, beverage, and animal nutrition ingredients — including probiotics, cultures, enzymes, and bioactive proteins. It is the most direct incumbent comparable to Bactolife, with overlapping precision-fermentation technology, food/feed customer base, and gut-health category positioning. Bactolife's CEO and COO both come from Novozymes.
  • Cargill: Global food and animal nutrition company with a large postbiotics and gut-health ingredients business (formerly through the Diamond V and postbiotic acquisitions). Overlaps with Bactolife in B2B functional ingredient sales to food, beverage, dietary supplement, and animal feed manufacturers. Bactolife's SVP US Liz Spence was previously Commercial Director and GM of Cargill's postbiotic business.
  • ADM (Archer Daniels Midland): Global nutrition and agricultural processor with a large-scale human and animal nutrition ingredients business, including flavors, probiotics, and functional ingredients produced via fermentation. Comparable to Bactolife in B2B food and feed ingredient supply, with significantly larger scale and customer reach.
  • Kerry Group: Irish-headquartered global taste and nutrition company selling ingredients (probiotics, postbiotics, enzymes, bioactive proteins) to food, beverage, and supplement manufacturers. Comparable to Bactolife in B2B functional ingredient sales, with adjacent gut-health technology (including GanedenBC30 probiotics) and broader portfolio diversification.
  • IFF (International Flavors & Fragrances): Global ingredients company with a Health & Biosciences division producing cultures, probiotics, enzymes, and food ingredients via microbial fermentation (via the Danisco acquisition). Comparable to Bactolife in precision-fermentation-derived functional ingredients, with greater scale and broader category coverage.

Direct peers

  • BioGaia: Swedish probiotics specialist developing Lactobacillus and Bifidobacterium strains for gut health, sold as dietary supplements and as functional food/infant formula ingredients globally. Direct peer to Bactolife in the gut-health ingredient category, though BioGaia's mechanism (probiotics) differs from Binding Proteins; both target infant formula, supplements, and clinical nutrition.

Emerging players

  • Perfect Day: US-based precision fermentation company producing animal-free whey and casein proteins for food and nutrition applications using a similar fermentation platform to Bactolife's. Comparable as a fellow precision-fermentation functional protein company targeting B2B food and nutrition customers, though Perfect Day focuses on dairy-analogue proteins rather than gut-health binding proteins.
  • The EVERY Company: US-based precision fermentation company (formerly Clara Foods) producing animal-free egg proteins and other functional proteins via microbial fermentation. Comparable to Bactolife in precision-fermentation-derived functional proteins targeting food and supplement applications, with a similar B2B ingredient business model.
  • Vivici: Dutch B2B ingredients startup producing precision-fermentation dairy proteins (whey, casein) for food, beverage, and nutrition applications. Comparable to Bactolife as a fellow emerging precision-fermentation protein company targeting the B2B functional food ingredient market, with similar technology platform and growth stage.

Regional players

  • Lallemand: Canadian-headquartered global producer of yeast, bacteria, and fermentation-derived ingredients for food, beverage, animal nutrition, and human health applications. Comparable to Bactolife in fermentation-derived functional ingredients and in animal feed (probiotics) for swine — a directly overlapping customer base in piglet gut health.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Bactolife social profiles

Digital presence

Bactolife financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bactolife leadership team

Management profile

Number of profiles

Profiles23 records

Bactolife funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bactolife M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bactolife

What does Bactolife do?

Bactolife develops and manufactures proprietary Binding Proteins — milk-inspired proteins derived from natural camelid immunoglobulins that selectively bind and neutralize harmful microbes and their metabolites in the gastrointestinal tract without disrupting beneficial microbiome components. These proteins are produced via scalable precision fermentation and sold as functional ingredients to food, beverage, dietary supplement, and animal feed manufacturers under the Helm™ brand for human health applications and as dedicated animal health feed additives.

Is Bactolife a public or private company?

Bactolife is a private company. It is classified as venture growth investor backed and is currently operating.

When was Bactolife founded?

Bactolife was founded in 2017. It employs 51 to 100 people.

Where is Bactolife based?

Bactolife is headquartered in Copenhagen, Denmark, in the Europe region.

How does Bactolife make money?

Three revenue lines are on record. Food Ingredient Sales are the primary driver. The others are feed Ingredient Sales and ingredient Licensing (Helm Brand).

Who are Bactolife's main competitors?

Broad incumbents on record are Novonesis, Cargill, ADM (Archer Daniels Midland), Kerry Group and IFF (International Flavors & Fragrances). BioGaia is listed as a direct peer. Emerging players are Perfect Day, The EVERY Company and Vivici. Lallemand is listed as a regional player.

Does Bactolife have an API?

No public API is recorded for Bactolife.

What industry is Bactolife in?

Bactolife's product category is Gut Health Biotech Ingredients. Its primary akta.pro industry code is AFAHAHAJ, Specialized Dairy Nutrition Base Powder & Premix Manufacturing (Vitamin/Mineral/Functional Premixes). Its NAICS code is 3111 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
nutraingredients.comBeyond basic biotics: Gut health ingredients set for success in 2026The gut health ingredients market is evolving beyond traditional probiotics and prebiotics, with emerging categories including postbiotics, medicinal mushrooms, sea moss, and binding proteins gaining clinical support for functional food and drink applications. The UK digestive health supplements market generated $466.4 million in revenue in 2024 and is projected to reach $846.3 million by 2033, driven by consumer demand for scientifically backed, formulation-friendly solutions. Researchers from M2 Ingredients found that combined mushroom species produce superior prebiotic effects through synergistic interactions, while companies including Pura Collagen and Bactolife are commercialising novel gut health ingredients such as digestive collagen supplements and immunoglobulin-based binding proteins.Food & Drink InternationalBactolife closes Series B to advance precision-fermented protein ingredientBactolife completed a Series B funding round exceeding €30 million to support the development and commercial rollout of precision-fermented protein ingredients for food, nutrition, and feed markets. The Denmark-based company plans to launch its first ingredients in the US in 2026, targeting markets in Asia and Europe afterward, with funding allocated to clinical studies, production scale-up, and global expansion.ArcticstartupWith €30M+ Series B, Danish Bactolife prepares shift from R&D to commercial scaleCopenhagen-based Bactolife has raised over €30 million in a Series B funding round, led by Cross Border Impact Ventures and EIFO with participation from existing investors Novo Holdings and Athos, to advance its Binding Protein technology toward commercialization. The funding will support large-scale human clinical studies, scale manufacturing through precision fermentation, and enable the company's first human health product launch in the US planned for 2026, followed by expansion into European and Asian markets. The company also plans to make its technology accessible to women and children in low- and middle-income countries as part of its global health strategy.BebeezWith €30M+ Series B, Danish Bactolife prepares shift from R&D to commercial scale – BeBeez InternationalCopenhagen-based Bactolife has raised more than €30 million in a Series B round to advance its Binding Protein technology from development toward commercialization, with the first human health product launch planned for the US in 2026. The round was led by Cross Border Impact Ventures and EIFO, with continued backing from existing investors Novo Holdings and Athos. The funding will support large-scale human clinical studies, scale manufacturing through precision fermentation, and enable market entry across North America, Europe, and Asia, while also making the technology accessible to women and children in low- and middle-income countries.GreenqueenBactolife Targets Gut Health Market with $35M Funding for Binding ProteinsDanish biotech startup Bactolife has raised €30M ($35M) in Series B funding, led by Cross Border Impact Ventures and Danish state fund EIFO with participation from existing investors Novo Holdings and Athos, to launch its gut-health-boosting binding proteins in the US market and execute a human study programme. The binding proteins, produced through precision fermentation, will initially launch under the Helm ingredient brand in 2026 with further expansion planned to the EU and Asia. The company also aims to make these proteins accessible to women and children in low- and middle-income countries.Tech TourTech Tour Bio-based Industries 2025 Featuring the Next Generation of Sustainable SolutionsThe Tech Tour Bio-based Industries 2025 concluded in Wuppertal, Germany, on November 13, 2025, showcasing 38 startups advancing sustainable bio-based solutions. The event featured pitches from companies such as Bactolife, COLIPI, and Bayer partners, which have collectively raised over €225 million for innovations in biomanufacturing and circular technologies. Hosted by the Bio-based Industries Consortium and Circular Valley, the programme highlighted scaling opportunities within the EU's bioeconomy.GlobeNewswireNovozymes and Bactolife join forces to significantly reduce post weaning diarrhea and antibiotic use among weaner pigsNovozymes and Bactolife have signed an agreement to jointly develop and commercialize Ablacto+, a feed additive containing binding proteins intended to stabilize piglet guts and reduce post-weaning diarrhea. The partnership aims to significantly lower antibiotic consumption in the swine industry, addressing a major global health challenge that causes billions in annual losses. Novozymes holds global exclusive marketing rights for the product, which is expected to launch in 2026 following final development and large-scale trial results.GlobalaginvestingBactolife Raises €30M Series A to Commercialize Proprietary Binding ProteinsCopenhagen-based bioindustrial company Bactolife has closed a €30 million Series A funding round to commercialize its proprietary Binding Protein technology. The investment, led by ATHOS with participation from the Bill & Melinda Gates Foundation and Novo Holdings, will support the development of biological solutions aimed at reducing gastrointestinal infections and antimicrobial resistance in humans and animals.Tech.euBactolife's €30M in funding to commercialise gut health binding proteinsBactolife, a Danish biotech, raised €30 million in a round led by Athos with participation from the Bill & Melinda Gates Foundation and existing investors. The funding will support commercializing its gut health binding proteins and upscaling its technology platform. The company aims to accelerate partnerships and launch first product concepts for humans and animals.BactolifeBactolife Raises EUR 30 million in Series A Financing – BactolifeBactolife A/S has raised over EUR 30 million in a Series A financing round led by ATHOS, with participation from the Bill & Melinda Gates Foundation and Novo Holdings. The company intends to use these funds to commercialize its proprietary Binding Proteins technology for human and animal gut health and to strengthen its upscaling capabilities.